Form 4: Zenas BioPharma CEO Boosts Stake

Zenas BioPharma's CEO and Chairman, Leon O. Moulder Jr., acquired 36,928 shares of common stock at $20.85 per share through a trust, increasing his indirect beneficial ownership.

Summary

• Leon O. Moulder Jr., Zenas BioPharma's Chief Executive Officer and Chairman, acquired 36,928 shares of common stock.
• The acquisition was made on October 7, 2025, through the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008.
• The purchase price for these shares was $20.85 per share.
• Following this transaction, Moulder's indirect beneficial ownership through the Trust is 36,928 shares.
• His total indirect beneficial ownership, including shares held by Tellus BioVentures LLC, is 1,708,967 shares.
• He also directly beneficially owns 266,155 shares.
• Moulder disclaims beneficial ownership of shares held by the Trust and Tellus except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: The acquisition of shares by the CEO and Chairman is a strong positive signal, indicating high confidence in the company's future prospects and potentially undervalued stock.

Positives

• The Chief Executive Officer and Chairman of Zenas BioPharma, Leon O. Moulder Jr., acquired additional shares, signaling confidence in the company's future prospects.
• The purchase of 36,928 shares at $20.85 per share represents a direct financial commitment by top management.

Future Outlook

The filing does not provide specific forward-looking statements or guidance, focusing solely on the reported insider transaction.

Management Comments

• Leon O. Moulder Jr. serves as the Issuer's Chief Executive Officer and Chairman of its board of directors.
• Moulder disclaims beneficial ownership of securities held by the Leon O. Moulder, Jr. Revocable Trust and Tellus BioVentures LLC except to the extent of his pecuniary interest therein.

Industry Context

This insider purchase reflects a specific transaction by a key executive within Zenas BioPharma. While not directly indicative of broader industry trends, insider buying can sometimes signal executive confidence in a company's position or future within its sector, potentially contrasting with or reinforcing general market sentiment for biopharmaceutical companies.

Related Party Transactions

• The acquisition of shares was made by the Leon O. Moulder, Jr. Revocable Trust, of which the reporting person, Leon O. Moulder Jr., is a Trustee.
• Leon O. Moulder Jr. is also the Managing Member of Tellus BioVentures LLC, which holds a significant number of Zenas BioPharma shares.

Stakeholder Impact

• Shareholders: May experience increased confidence due to the CEO's personal investment, potentially leading to positive sentiment and stock price movement.
• Employees: Could perceive increased stability and management commitment, fostering a positive internal environment.

Key Dates

Recommendation

The significant purchase of company stock by the CEO and Chairman, Leon O. Moulder Jr., signals strong insider confidence in Zenas BioPharma's future. Such a direct financial commitment by top management often precedes positive developments or indicates a belief that the stock is currently undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Zenas BioPharma, ZBIO, Insider Purchase, Stock Acquisition, Leon O. Moulder Jr., CEO, Chairman, Form 4, Biopharma